{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:26:15Z","timestamp":1692714375025},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13300-016-0170-2","type":"journal-article","created":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T04:10:27Z","timestamp":1461557427000},"page":"309-320","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"7","author":[{"given":"Tomoyuki","family":"Katsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuyoshi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,25]]},"reference":[{"key":"170_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","volume":"12","author":"T Vilsb\u00f8ll","year":"2010","unstructured":"Vilsb\u00f8ll T, Rosenstock J, Yki-J\u00e4rvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"170_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s13340-013-0109-z","volume":"4","author":"T Kadowaki","year":"2013","unstructured":"Kadowaki T, Tajima N, Odawara M, et al. Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetol Int. 2013;4:160\u201372.","journal-title":"Diabetol Int"},{"key":"170_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1463-1326.2012.01600.x","volume":"14","author":"ES Hong","year":"2012","unstructured":"Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14:795\u2013802.","journal-title":"Diabetes Obes Metab"},{"key":"170_CR4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1507\/endocrj.EJ12-0293","volume":"60","author":"T Katsuno","year":"2013","unstructured":"Katsuno T, Ikeda H, Ida K, Miyagawa J, Namba M. Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus. Endocr J. 2013;60:733\u201342.","journal-title":"Endocr J"},{"key":"170_CR5","doi-asserted-by":"crossref","unstructured":"UKPDS group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"issue":"Suppl. 3","key":"170_CR6","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/sj.ijo.0802173","volume":"26","author":"M Korytkowski","year":"2002","unstructured":"Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26(Suppl. 3):S18\u201324.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"170_CR7","doi-asserted-by":"publisher","first-page":"e0121988","DOI":"10.1371\/journal.pone.0121988","volume":"10","author":"S Sato","year":"2015","unstructured":"Sato S, Saisho Y, Itoh H, et al. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. PLoS One. 2015;10:e0121988.","journal-title":"PLoS One"},{"key":"170_CR8","doi-asserted-by":"crossref","unstructured":"Takai M, Ishikawa M, Maeda H, et al. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study. Diabetes Res Clin Pract. 2014;103:e30\u20133.","DOI":"10.1016\/j.diabres.2013.12.045"},{"key":"170_CR9","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1507\/endocrj.EJ12-0220","volume":"59","author":"M Takahara","year":"2012","unstructured":"Takahara M, Shiraiwa T, Kaneto H, Katakami N, Matsuoka TA, Shimomura I. Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy. Endocr J. 2012;59:1131\u20136.","journal-title":"Endocr J"},{"key":"170_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/dia.2012.0214","volume":"15","author":"Y Mori","year":"2013","unstructured":"Mori Y, Taniguchi Y, Miyazaki S, Yokoyama J, Utsunomiya K. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther. 2013;15:237\u201340.","journal-title":"Diabetes Technol Ther."},{"key":"170_CR11","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2337\/db09-1414","volume":"59","author":"KJ Hare","year":"2010","unstructured":"Hare KJ, Vilsb\u00f8ll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010;59:1765\u201370.","journal-title":"Diabetes"},{"key":"170_CR12","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1464-5491.2011.03331.x","volume":"28","author":"SL Ellis","year":"2011","unstructured":"Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28:1176\u201381.","journal-title":"Diabet Med"},{"key":"170_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2337\/dc11-0096","volume":"34","author":"U Kielgast","year":"2011","unstructured":"Kielgast U, Krarup T, Holst JJ, Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care. 2011;34:1463\u20138.","journal-title":"Diabetes Care"},{"key":"170_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","volume":"56","author":"YG Kim","year":"2013","unstructured":"Kim YG, Hahn S, Oh TJ, et al. Difference in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56:696\u2013708.","journal-title":"Diabetologia"},{"key":"170_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s13300-015-0105-3","volume":"6","author":"C Mathieu","year":"2015","unstructured":"Mathieu C, Shankar RR, Lorber D, et al. A randomized clinical trial to evaluate the efficacy and safety of co-administration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther. 2015;6:127\u201342.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-016-0170-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0170-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-016-0170-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:27:07Z","timestamp":1567816027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-016-0170-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,25]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["170"],"URL":"https:\/\/doi.org\/10.1007\/s13300-016-0170-2","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,25]]},"assertion":[{"value":"23 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}